Creating a new treatment to help the gut after radiation exposure
Official title: Development of a Novel Therapeutic for Mitigating Radiation-Induced Microbiome Dysbiosis and Acute Gastrointestinal Syndrome
Funded at Columbia University Health Sciences · NIH-11012255 · Data updated 2026-11-12
This study is testing a new treatment called MIIST305 to help protect your gut from damage caused by high doses of radiation, like what might happen in a nuclear event, by promoting healing and reducing inflammation.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $503,779 |
| NIH project number | 5U01AI172853-03 |
| Project ID | NIH-11012255 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have been exposed to high doses of radiation, particularly in scenarios involving mass casualty events.
✕Less likely to help
Patients who have not been exposed to radiation or those with pre-existing severe gastrointestinal conditions may not benefit from this research.
What this research studies
This research focuses on developing a novel therapeutic agent, MIIST305, aimed at mitigating the harmful effects of radiation on the gastrointestinal (GI) tract. It targets microbiome dysbiosis and acute gastrointestinal syndrome that can occur after high-dose radiation exposure, such as from a nuclear event. The approach involves administering the drug after radiation exposure to reduce cell death, inflammation, and promote tissue regeneration. The research utilizes advanced gene sequencing techniques to understand the microbiome changes and the therapeutic effects of MIIST305.
Why it matters
Potential benefit: If successful, this research could provide a critical treatment option for patients suffering from radiation-induced gastrointestinal injuries.
How similar studies have gone: Preliminary studies have shown promising results with similar therapeutic approaches in animal models, indicating potential for success in human applications.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Broustas, Constantinos G. — Columbia University Health Sciences
- Study coordinator: Broustas, Constantinos G.
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
From Symbiosis to Dysbiosis: How Resolving Inflammation Could Restore Your Mouth’s Balance
This grant explores how turning off the harmful inflammation in periodontitis and promoting natural healing could help restore the mouth’s healthy balance.
-
Antibiotics, gut health, and skin reactions in kids
A small study in children will look at whether antibiotic use and gut bacteria play a role in hives and related symptoms that children sometimes get after antibiotics.
-
Novel therapeutic to protect the gut after radiation
A new GI-directed treatment given after radiation exposure may reduce gut damage and improve survival in people exposed to high-dose radiation.
-
A new GI-focused treatment to reduce radiation damage after exposure
A potential GI-targeted therapy given after radiation exposure may help protect the gut and improve survival in people affected by radiation injuries.
-
How a mouth bacterium might fuel gum disease and heart risk
A small study will look at how a bacterium in the mouth that makes a reactive chemical (methylglyoxal) could drive gum inflammation and changes in the mouth’s bacteria, possibly linking to heart disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.